APRE Aprea Therapeutics, Inc.: Earnings per share for the last 12 months

Aprea (APRE) - corporate logo

The annual volatility of TTM net income per share on the GURU.Markets chart demonstrates EPS growth dynamics, where the value 67.10 captures the metric level. Aprea Therapeutics (APRE) is valued for its innovations in restoring DNA responses in oncology. A team of elite scientists operates here under conditions of academic freedom. However, the business remains vulnerable due to its dependence on the outcomes of early clinical trials for targeted drugs.

Aprea (APRE) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/16/2026

APRE (Aprea): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:APRE Aprea Therapeutics
Flagship merchandise of Aprea Therapeutics Inc.

Investors must weigh the potential return against critical business risks. By analyzing the annual growth rate of earnings per share (ttm), we assess the resilience of net income to macroeconomic shocks through a daily calculation of growth rates. The dynamics of this indicator reveal hidden vulnerabilities or prerequisites for earnings acceleration. For Aprea Therapeutics (APRE), such a metric is critical due to the high capital burn rate during clinical trials. A negative trend here confirms financial pressure stemming from the risks of biological platform failures.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months